A new study has revealed that resistance to a major class of breast-cancer drugs is not a single, predictable event but an evolutionary tug-of-war shaped by both the tumor’s genetic makeup and the exact medicine used. In estrogen receptor-positive breast cancer, researchers found that mutations in the estrogen receptor gene, ESR1, can redirect which cancer-cell clones survive treatment, alter the cells’ regulatory programs and influence their ability to spread. The work suggests that two patients whose tumors become resistant to therapy may arrive at that outcome through very different biological routes—even when they receive drugs from the same class. The findings could help explain why switching treatments after resistance sometimes works and sometimes fails, and why the order or combination of therapies may matter as much as the drugs themselves.
The study, published in Genome Medicine, examined acquired resistance to CDK4/6 inhibitors, drugs that have transformed the treatment of advanced estrogen receptor-positive breast cancer. These medicines are commonly given with endocrine therapy, which blocks estrogen signaling or interferes with the estrogen receptor. CDK4/6 inhibitors attack a different part of the growth machinery: they restrain cyclin-dependent kinases 4 and 6, proteins that help push cells from a resting phase into DNA replication. By interrupting this cell-cycle transition, the drugs can slow or stop tumor expansion. Yet most metastatic tumors eventually resume growing. Activating ESR1 mutations are already recognized as a frequent route to resistance against endocrine therapy, but their independent contribution to resistance against CDK4/6 inhibition has been far less clear.
To isolate that contribution, the researchers built an isogenic model using MCF7 breast-cancer cells. The cells were genetically matched except for the form of estrogen receptor they carried: one group expressed the normal, or wild-type, receptor, while another expressed the Y537S mutant form of ER, a common activating ESR1 mutation. This design allowed the investigators to compare resistance evolution while holding much of the cellular background constant. They then exposed the cells to either palbociclib or abemaciclib, two CDK4/6 inhibitors, and followed the populations over time. The team combined high-complexity DNA barcoding with molecular profiling, effectively giving thousands of cancer-cell lineages unique genetic “names” that could be tracked as treatment removed some populations and allowed others to expand.
This lineage-tracing strategy captured a feature that conventional drug-sensitivity tests can miss. A tumor may appear to be a single mass, but it is typically a crowded ecosystem containing many related subclones. Some may already carry mutations that confer a survival advantage, while others may not be genetically resistant but can temporarily alter their behavior when exposed to stress. As treatment continues, the drug changes the population’s environment. Sensitive clones shrink or disappear, resistant clones expand and previously minor populations can become dominant. The researchers observed progressive clonal selection under both inhibitors, with some evolutionary paths diverging and others partially converging on similar resistant states. In other words, different starting populations could reach overlapping biological solutions, even though the precise clones and regulatory changes involved were not identical.
The effect of the estrogen-receptor mutation was especially pronounced during selection with palbociclib. In cells carrying ER-Y537S, the mutation substantially reshaped both clonal evolution and epigenetic evolution—the changes in chromatin accessibility and gene regulation that influence which genes a cell can use without altering the DNA sequence itself. The same mutation had a weaker effect under abemaciclib selection. This difference is important because palbociclib and abemaciclib inhibit the same broad protein targets but are not biologically interchangeable. They differ in potency, selectivity, dosing behavior and effects on cell-cycle control, and abemaciclib can inhibit additional kinases at clinically relevant concentrations. The results indicate that each drug creates its own selective landscape, favoring distinct combinations of pre-existing traits and treatment-induced adaptations.
The study also showed that resistance is not explained by genetics alone. Single-cell RNA sequencing revealed pronounced transcriptional heterogeneity as cells were passaged and exposed to drug selection. Individual cells within the same resistant population could occupy different functional states, including states associated with altered proliferation, stress responses, lineage programs and cellular plasticity. Plasticity refers to a cell’s ability to shift its phenotype in response to changing conditions. A cell that temporarily enters a slow-cycling or altered regulatory state may survive therapy without immediately acquiring a new resistance mutation. If treatment persists, that state can provide time for more stable genetic or epigenetic changes to emerge. This layered process helps explain why resistance can develop gradually and why a resistant tumor may remain vulnerable to a different therapeutic pressure.
The researchers extended their analysis beyond cultured cells by studying patient tumor samples. They found that ESR1 mutations were enriched in clinical tumors that had acquired resistance to CDK4/6 inhibitors. In paired biopsies taken before and after treatment, mutant cancer-cell populations expanded until they approached clonality, meaning that the mutation was present in nearly all of the sampled tumor cells. Such expansion is a strong sign of treatment-driven selection: the mutation may have been present in only a minority of cells initially, but therapy created conditions in which those cells gained a decisive advantage. The finding does not mean that every resistant tumor is dominated by an ESR1 mutation, nor that the mutation alone explains resistance. Instead, it places the receptor mutation within a broader evolutionary process involving competing clones, adaptable cell states and drug-specific pressures.
Experiments in mice added another layer to the picture by tracing barcoded cancer cells in mammary tumors, local recurrences and distant metastases. The investigators observed site-specific clonal outgrowth in tumors carrying mutant estrogen receptors. Different anatomical sites favored different subclones, suggesting that the tissue environment can act as another filter during cancer evolution. Some subpopulations overlapped between metastatic lesions and CDK4/6-inhibitor-resistant tumors, supporting the possibility that particular cancer-cell groups can perform a dual role: surviving treatment in one setting while also possessing traits that help them colonize distant organs. However, the overlap was only partial. Resistance and metastatic spread therefore appear related but not identical, with each process selecting for some shared and some distinct characteristics.
The implications extend to how oncologists think about treatment after CDK4/6 inhibitor failure. The results argue against viewing resistance as a uniform condition that can be treated with one universal sequence of drugs. Instead, the most effective next therapy may depend on whether a tumor carries an activating ESR1 mutation, which CDK4/6 inhibitor was used first and which cellular states emerged during treatment. Molecular tests that identify receptor mutations are already relevant to endocrine-treatment decisions, but the new work suggests they could also help interpret the evolutionary history of CDK4/6 inhibitor resistance. Future strategies might combine drugs that target estrogen-receptor signaling with agents aimed at cell-cycle control or the adaptive states that allow cancer cells to persist. Such approaches will require clinical testing, because findings from engineered cell models and mouse xenografts cannot by themselves predict patient benefit.
The central message is that cancer resistance is a moving target rather than a fixed lock that one key fails to open. By combining lineage tracing, DNA sequencing, chromatin analysis and single-cell transcriptomics, the researchers were able to watch resistant populations emerge at several biological scales—from individual clones to shifting gene-expression states and tumor growth in different organs. Their findings show that ESR1 mutation status and inhibitor choice jointly shape the route a tumor takes under treatment. Mapping those routes could make resistance more predictable and could encourage treatment plans designed not merely to kill the dominant cancer population, but also to prevent minor, adaptable clones from becoming the next dominant threat.
